Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Regeneron Pharmaceuticals Inc (REGN) vs Stitch Fix Inc (SFIX) Price & Performance

Regeneron Pharmaceuticals IncTrade
Stitch Fix IncTrade

Price performance (Past 24H)

Key statistics

Regeneron Pharmaceuticals Inc vs Stitch Fix Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Stitch Fix Inc trades at $2.9 (market cap $396.27M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 210.5× Stitch Fix Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Stitch Fix Inc pays none. Which is the better fit depends on your goals.

REGNSFIX
Market Cap
$83.43B$396.27M
Sector
HealthConsumer Cyclical
52-Week High
$852.03$5.80
52-Week Low
$555.51$2.89
Enterprise Value
$78.14B$283.99M
Dividend Yield
0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

Stitch Fix Inc

Stitch Fix (SFIX) trades at $2.97, down 2.62% on the day, as the stock faces technical bearish pressure despite showing fundamental improvements. The company has demonstrated progress in its turnaround with three consecutive quarterly earnings beats and narrowing losses, though it remains unprofitable with a -1.43% net margin. Recent news highlights ongoing legal challenges and AI-driven growth initiatives, while analyst sentiment remains cautious with 64% hold ratings.

The outlook suggests a company in transition - improving operational metrics and debt-free balance sheet provide stability, but sustained profitability remains the key challenge. Near-term catalysts include Q2 2026 earnings results and continued execution of AI personalization strategy, though competitive pressures and consumer spending volatility present ongoing risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN

About Stitch Fix Inc

Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.

Read more on SFIX